For research use only. Not for therapeutic Use.
Glecaprevir（Cat No.:I006612）is a potent, direct-acting antiviral agent used to treat hepatitis C virus (HCV) infections. It is an NS3/4A protease inhibitor that blocks the cleavage of HCV polyproteins, halting viral replication. Glecaprevir is effective against multiple HCV genotypes and is commonly used in combination therapies, such as with pibrentasvir, to achieve sustained virologic response. Its high barrier to resistance and efficacy in difficult-to-treat populations make it a cornerstone in HCV therapy. Glecaprevir is also essential for studying antiviral mechanisms and optimizing HCV treatment strategies.
| Catalog Number | I006612 |
| CAS Number | 1365970-03-1 |
| Synonyms | ABT-493; A-1282576; ABT493; A1282576; ABT 493; A 1282576;(33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3, |
| Molecular Formula | C38H46F4N6O9S |
| Purity | ≥95% |
| Documentation | |
| Target | Metabolic Enzyme/Protease |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (1R,14E,18R,22R,26S,29S)-26-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropyl)sulfonylcarbamoyl]cyclopropyl]-13,13-difluoro-24,27-dioxo-2,17,23-trioxa-4,11,25,28-tetrazapentacyclo[26.2.1.03,12.05,10.018,22]hentriaconta-3,5,7,9,11,14-hexaene-29-carboxamide |
| InChI | InChI=1S/C38H46F4N6O9S/c1-35(2,3)28-32(50)48-19-20(17-24(48)30(49)46-37(18-21(37)29(39)40)33(51)47-58(53,54)36(4)14-15-36)56-31-27(43-22-9-5-6-10-23(22)44-31)38(41,42)13-8-16-55-25-11-7-12-26(25)57-34(52)45-28/h5-6,8-10,13,20-21,24-26,28-29H,7,11-12,14-19H2,1-4H3,(H,45,52)(H,46,49)(H,47,51)/b13-8+/t20-,21+,24+,25-,26-,28-,37-/m1/s1 |
| InChIKey | MLSQGNCUYAMAHD-ITNVBOSISA-N |
| SMILES | CC1(CC1)S(=O)(=O)NC(=O)[C@]2(C[C@H]2C(F)F)NC(=O)[C@@H]3C[C@@H]4CN3C(=O)[C@@H](NC(=O)O[C@@H]5CCC[C@H]5OC/C=C/C(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C |
| Reference | <br /> |
